NASDAQInformation TechnologySoftware - ApplicationSnapshot 2026-07-31
Reading VERX? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Application Software is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Full-year 2026 revenue reaches at least $823.5 million: $827.5 million vs $823.5 million.
View ThesisRevenue growth is slowing — up about 12% over the past year and decelerating.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 68% in its worst 12-month stretch.
View RiskVERX's growth trajectory hinges on achieving at least $823.5 million in revenue for the full year 2026, as this is critical to justifying its current valuation. Recent performance has been steady, but the latest results indicate that the company is under pressure to meet these revenue expectations. Currently, the price reflects less growth than forecasted, with peer multiples implying a price about 16% above where it trades, suggesting that the market may not fully appreciate its potential. A specific risk is the possibility of a guidance cut on the next call, which our model estimates has a 23% chance of occurring, potentially leading to further downward pressure on the stock. Peer multiples imply a price about 16% above where it trades; this read is provisional.
Trailing returns as of 2026-07-31. VERX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 16 analysts currently covering VERX (as of Jul 2026).
Based on 4 Wall Street analysts offering 12-month price targets for VERX in the last 4 months.
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Application Software — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Advances: Focus on AI-enabled transformation
Extending pipeline aligns with AI-enabled transformation goals.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $12.91
The last 12 months of price, then the range of analyst 12-month targets from today’s $12.91.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Focus on AI-enabled transformation
FDA acceptance supports AI-enabled transformation in drug development.
Advances: Increase revenue guidance
BLA acceptance could enhance revenue guidance for Vertex.
